Reimbursement Pathways for Psychedelic Therapies: An Overview

Overview of Psychedelic Therapies and Reimbursement Challenges

The Promise of Psychedelic Therapies

Mental health disorders impose a severe and growing societal and economic burden across Europe. Both national governments and the European Union (EU) now recognise that current treatments often fail to meet patients' needs. Treatment resistance is a significant challenge, with approximately 30-50% of patients across various mental health conditions showing limited or no response to conventional therapies. These ‘treatment-resistant’ patients face limited therapeutic options and incur the highest medical costs.

Psychedelic[1]1 therapies[2]2 have emerged as a promising option for conditions like depression, post-traumatic stress disorder (PTSD), and addictions. Although these interventions come with significant historical context and face multiple scientific and regulatory challenges, they represent the next wave of innovation in mental healthcare. Similar to previous therapeutic frontiers like cell and gene therapies, these interventions may also encounter significant reimbursement barriers.

For patients with 'treatment resistant' conditions, who represent approximately one-third of all cases, the current situation is particularly dire. The emergence of psychedelic therapies offers new hope, with research spanning academic, commercial, and non-profit initiatives. These novel approaches represent a potential paradigm shift in mental health treatment for those who have exhausted conventional treatment approaches.

PTSD is one of the most promising fields for the application of psychedelic therapies. Phase III clinical trials of MDMA therapy have demonstrated remarkable efficacy, with 67% of participants no longer meeting PTSD diagnostic criteria after three sessions, compared to 32% in the placebo group (Mitchell et al., 2021; Mitchell et al., 2023).

For treatment-resistant depression (TRD), psilocybin therapy has shown considerable promise. A large-scale Phase IIb clinical trial across 22 sites in Europe and North America, involving 233 patients with TRD, demonstrated that a single 25mg dose of synthetic psilocybin, administered with psychological support in a controlled setting, led to a significantly greater reduction in depression symptoms at the three-week primary endpoint compared to the 1mg control group (Goodwin et al., 2022).

Ketamine-based therapies have already achieved regulatory recognition for depression, including TRD. In 2019, esketamine nasal spray received approval from the FDA and EMA, representing the first psychedelic treatment to gain widespread regulatory acceptance (EMA, 2019; FDA, 2019). The FDA later expanded its indication as a standalone treatment for TRD, eliminating the requirement for concurrent antidepressant medications (Johnson & Johnson, 2025). When evaluated in Germany's health technology assessment process, it received the second highest possible clinical benefit rating for TRD treatment, marking a significant milestone in the acceptance of novel psychiatric interventions (G-BA, 2023).

In addiction treatment, psychedelic therapies are showing promise across multiple substances. Early research in psilocybin therapy for smoking cessation showed 80% abstinence rates at six-month follow-up (Johnson et al., 2014), leading to expanded research, including a National Institute on Drug Abuse-sponsored double-blind trial of 66 patients with $1.5 million in funding (NIDA, 2023). For alcohol use disorder, both psilocybin and ketamine therapies have demonstrated encouraging results. Psilocybin therapy showed significant reductions in heavy drinking days (Bogenschutz et al., 2022), while ketamine therapy achieved a remarkable 86% abstinence rate over six months post-treatment (Grabski et al., 2022; Awakn, 2022). For opioid use disorder, NIDA has committed $15 million to investigate psilocybin's potential in reducing opioid cravings among patients on methadone maintenance therapy (B.More, 2024).

Regulatory approaches to psychedelic therapy have evolved significantly over time. Switzerland pioneered the medical use of LSD and MDMA through specialised clinics from 1988 to 1993. Since 2014, it has allowed restricted therapeutic access to multiple psychedelics (including LSD, MDMA, and psilocybin) through compassionate use programs (Liechti, 2019). Similar compassionate use frameworks in Canada provide controlled access to psilocybin and MDMA to patients with demonstrated unmet needs (Health Canada, 2023). More recently, Australia made a landmark decision to reschedule psilocybin and MDMA for therapeutic use under controlled circumstances, allowing psychiatrists to prescribe these treatments for specific mental health conditions (TGA, 2023).

In the United States, state-level initiatives have emerged on a different trajectory. Oregon and Colorado have established frameworks for regulated access to psilocybin services that operate separately from medical frameworks (Oregon Health Authority, n.d.; Colorado Department of Regulatory Agencies, n.d.). While groundbreaking, these state programs represent a distinct approach from the medical models seen in other countries.

These diverse regulatory approaches reflect different responses to mounting clinical evidence and urgent patient needs. Medical models like those in Switzerland, Canada, and Australia emphasise therapeutic frameworks with established clinical protocols and safety controls. Meanwhile, state-level U.S. initiatives offer insights into alternative regulatory structures. Together, these varied approaches provide valuable data and experience to inform future policy development in other jurisdictions.

Current Reimbursement Landscape

In Europe, a new medicine must demonstrate safety and effectiveness through clinical trials. After regulatory approval by the European Medicines Agency (EMA) or national agencies, each country independently assesses whether the medicine should be included in its public healthcare system. Health technology assessment (HTA) bodies evaluate its benefits, risks, and costs compared to existing treatments before determining reimbursement coverage.

Despite encouraging clinical results, emerging psychedelic therapies will potentially face significant reimbursement obstacles that could create barriers to patient access. Reimbursement frameworks work best for simpler pharmaceutical prescribing models. They are often not optimised to evaluate and reimburse more complex treatment protocols, such as combining drug administration with supportive psychotherapeutic care. Implementation may also be challenging with respect to arranging local funding to establish a new care pathway.

The challenges facing psychedelic therapies mirror those encountered by advanced therapies such as cell and gene treatments, where significant improvements in efficacy and patient outcomes confronted substantial reimbursement barriers. These barriers included high upfront costs for therapy, limitations in HTA methodologies related to long-term outcomes analysis, and the need for new care pathways and local infrastructure.

The historical context of psychedelic compounds, drug scheduling controls, and implementation challenges within existing healthcare systems add further complexity. Additionally, there are practical and methodological challenges in meeting the gold standard for evidence reviews, particularly in conducting double-blinded randomised controlled trials (RCTs) due to the noticeable psychoactive effects and establishing comparisons against existing standards of care.

The cost burden of psychedelic therapies presents a significant access barrier. Current ketamine and esketamine treatments typically range from €3,000 to €12,000 per patient for a course of treatment lasting between 4 to 12 weeks, accounting for medication costs, clinical supervision, and clinician time. Future psychedelic treatment costs may reach even higher due to more intensive therapeutic protocols, drug costs (influenced by patents and market exclusivity), and dedicated treatment facilities. Without insurance coverage or reimbursement from national health systems, these costs will be prohibitive for most patients.

The current reimbursement landscape for novel mental health treatments varies significantly across Europe. While esketamine (Spravato) has achieved reimbursement in some countries, access to ketamine treatments often relies on out-of-pocket payment through private clinics, limiting availability to those with substantial financial resources.

For emerging psychedelic therapies, healthcare payers are likely to express even greater hesitancy due to several factors:

1. Regulatory Complexity: International conventions classifying substances like psilocybin and MDMA as Schedule I drugs complicate their medical adoption and integration into healthcare systems.

1. Evidence Requirements: Despite promising clinical results, traditional HTA frameworks and payer expectations for comparative data and evidence packages may not align well with the unique characteristics of psychedelic therapies.

1. Health System Integration Challenges: The perceived need for specialised settings, trained therapists, and multi-hour dosing sessions poses logistical and financial challenges that current reimbursement systems would find difficult to handle.

The absence of clear regulatory, reimbursement, and access pathways for emerging psychedelic therapies creates significant uncertainty for multiple stakeholders. Healthcare providers may hesitate to invest in training and infrastructure without assured compensation pathways. Similarly, developers and investors face challenges in planning appropriate clinical studies that will satisfy both regulatory and reimbursement requirements while building necessary health system infrastructure. The experience with ketamine and esketamine integration demonstrates that these challenges are real and suggests that the barriers for emerging psychedelics may be even more substantial without proactive planning and stakeholder engagement.

Purpose of the Report

This report addresses challenges to reimbursement and access of psychedelic therapies in Europe. By exploring how these treatments can integrate into European healthcare systems, the report aims to bridge the gap between clinical results and patient access. Through analysis of the current landscape, the report identifies barriers to reimbursement and proposes solutions within existing frameworks.

Key objectives include:

• Mapping the Reimbursement Landscape: Providing a clear and detailed overview of current reimbursement pathways and insurance coverage across Europe, focusing on Germany, the Netherlands, the United Kingdom, and the Czech Republic. This involves identifying gaps specific to psychedelic therapies and understanding how existing reimbursement and insurance models can accommodate or hinder their integration.

• Stakeholder Engagement: Summarising insights from engaging with payers, regulatory bodies, drug developers, healthcare professionals, and patient advocacy groups. The report captures the multifaceted challenges and opportunities associated with reimbursing psychedelic therapies by incorporating diverse perspectives.

• Identifying Challenges and Solutions: The report highlights the barriers to reimbursement, including regulatory uncertainties, clinical evidence requirements, economic considerations, and infrastructural needs. It proposes practical recommendations for integration, such as potential reimbursement models, policy reforms, and strategies for demonstrating value to payers.

• Facilitating Access: Offering strategies to make psychedelic therapies accessible within existing healthcare frameworks. This includes outlining steps for integrating these therapies into standard care, addressing infrastructural and training requirements, and ensuring that reimbursement mechanisms support equitable patient access.

Key Findings

Potential Barriers to Reimbursement

• Evidence Assessment Challenges: HTA bodies and payers may struggle to evaluate psychedelic therapy trials due to methodological complexities, such as difficulties with blinding and comparative effectiveness data. The unique nature of these trials creates tension between meeting regulatory requirements for marketing authorisation and generating the comparative evidence typically expected for reimbursement decisions.

• Regulatory and Policy Hurdles: The pathway for psychedelic therapies faces multiple regulatory challenges throughout development, approval, and reimbursement: EMA authorisation, national drug control requirements, and country-specific healthcare system approvals. This multi-layered regulatory framework creates complex barriers to widespread adoption.

• Infrastructure Limitations: Successful implementation requires appropriately configured therapeutic spaces and trained professionals, but healthcare systems face significant workforce shortages, particularly in mental healthcare. This challenge is compounded by limited psychotherapy coverage in public healthcare systems and existing barriers such as long waiting times, additional fees, and session restrictions.

• Economic and Cost Considerations: High upfront costs pose a significant barrier, even for products without psychotherapeutic care components, due to patented compound pricing, specialised staffing requirements, and monitoring needs. This cost challenge is particularly stark given the relatively low cost of many standard treatments, which often include generic drugs.

• Stigma and Ethical Concerns: Historical attitudes and ethical considerations shape how healthcare providers, policymakers, and the public view psychedelic treatments, which can delay acceptance and funding.

Differences Across Countries

• Germany: Reimbursement in Germany can be almost immediate after regulatory approval, but Germany’s rigorous HTA processes require high-quality clinical evidence and comparison to the existing standard of care for the benefit assessment. Navigating HTA evaluations to secure a favourable reimbursed price requires proactive engagement and alignment on clinical studies with the GBA.

• United Kingdom: The UK has progressive initiatives like the Innovative Licensing and Access Pathway (ILAP) which aims to support high-value therapies to the market. However, integration into the NHS for innovative therapies requires demonstrating clinical effectiveness and cost-effectiveness at the national HTA level and navigating complex local funding and access decision-making.

• The Netherlands: The country's liberal regulatory approach and insurers' open approach to different funding models make it more favourable for pilot programs and real-world evidence collection. Still, reimbursement for novel therapies faces scrutiny for economic value and scalability at the national HTA and insurer levels.

• Czech Republic: With established ketamine clinics and an active approach to novel mental health treatments, the Czech Republic is exploring regulatory pathways and clinical trials for psychedelic therapies. Whereas the country offers an advanced ecosystem for development, its innovative insurer landscape is beginning to work with clinics on reimbursement models, though broader infrastructure for widespread implementation remains limited.

Stakeholder Insights

• Developers: Expressed need for clearer guidance on trial design requirements, more tailored HTA methodologies, and practical agreements regarding reimbursement arrangements and long-term follow-up data collection.

• Payers: Highlighted risk aversion, budget constraints, and the need for clear economic models demonstrating direct benefits—with potential consideration of indirect benefits—of psychedelic therapies.

• Providers: Pointed to workforce shortages and the lack of standardised training programs as barriers to scaling implementation.

• Policymakers: Acknowledged the need for updated regulatory frameworks and special access pathways to enable real-world data collection and phased rollouts.

• Advocacy Groups: Stressed the importance of public education campaigns and ethical guidelines to counter stigma and ensure equitable access.

Actionable Recommendations

Strengthen Clinical Evidence Generation

• Comparator Trials: Where feasible, prioritise head-to-head comparisons against standard treatments, particularly for countries like Germany, where such evidence is critical for favourable pricing and reimbursement decisions.

• Innovative Trial Designs: Where standard clinical trial approaches present specific challenges for psychedelic therapies, drug developers should consider adaptive protocols, active placebos, or hybrid (factorial) models that assess the relative contributions of drug and therapy components. Early engagement with regulators and Health Technology Assessment (HTA) bodies can ensure alignment with evidence expectations.

• Long-Term Data Collection: Incorporate extended follow-ups and real-world evidence pilots to address uncertainties about the durability of therapeutic effects and economic impact. Establish registries for post-market monitoring to support long-term evaluations.

• Independent Research Initiatives: Foster state-funded research programmes and multi-stakeholder collaborations beyond industry-sponsored trials to generate evidence. These studies can complement commercial development programmes and address broader public health questions.

Enhance Regulatory and Policy Pathways

• Leverage Enhanced Regulatory Pathways: Engage with regulators through available mechanisms such as the UK's ILAP and the EU's PRIME pathways to facilitate deeper collaboration and dialogue with regulatory and access stakeholders throughout development.

• Special Access Programmes: Introduce phased (pilot) rollout mechanisms and conditional approvals to enable earlier access while collecting real-world data to address uncertainties.

• Standardised Guidelines for Controlled Substances: Collaborate with policymakers to streamline frameworks for rescheduling and clarify requirements for psychedelic therapies.

Optimise HTA, Economic Modelling and Pricing Strategies

• HTA Methodology: There is a need for tailored HTA guidance and methodologies to guide both developers and assessors through acceptable evidence approaches on psychedelic-specific challenges such as blinding and bias, comparator choice, and drug plus psychotherapeutic considerations.

• Comprehensive Economic Evaluations: Develop cost-effectiveness models that demonstrate both direct and indirect benefits—such as improved productivity and reduced caregiver burden—to better demonstrate societal value to a broad set of stakeholders.

• Flexible Pricing Approaches: Propose outcome-based agreements, risk-sharing frameworks, and managed entry schemes to mitigate payer concerns about initial high costs and performance uncertainty.

Implement Flexible Reimbursement Approaches

• Performance-Based Contracts: Developers and payers should consider adopting reimbursement models tied to measurable patient outcomes to offset uncertainties about longer-term effectiveness.

• Bundled Payments: Where not currently in place, payers should consider developing integrated payment structures that can account for both drug and psychotherapeutic costs, streamlining billing and ensuring comprehensive coverage.

• Longer Term Patient Management Payments: Payment mechanisms covering six months plus of patient management should be considered to allow providers to make treatment choices free from the influence of short-term budget impact.

Build Implementation Infrastructure

• Dedicated Treatment Rooms: Establish appropriate therapeutic environments within existing healthcare facilities or new spaces, ensuring settings are suitable for psychedelic sessions while meeting safety and regulatory requirements. Multi-stakeholder guidance is needed to define the essential characteristics of these therapeutic spaces.

• Professional Training Standards: Define requirements and establish consensus on core competencies for healthcare providers delivering psychedelic therapy.

• Workforce Development: Support the creation of standardised training programs and continuing education frameworks to build and maintain a qualified provider network.

• Clinical Protocols and Guidelines: Develop standardised treatment protocols covering patient screening, preparation sessions, medication administration, therapeutic support during sessions, integration work, and follow-up care.

Address Societal and Ethical Barriers

• Educational Campaigns: Advocacy groups should lead efforts to reduce stigma through public education, balanced media engagement, and patient testimonials.

• Ethical Guidelines and Oversight: Establish professional standards for informed consent, therapist training, and treatment monitoring for patient safety.

• Equitable Access Policies: Eliminate cost barriers to psychedelic therapies by mandating insurance reimbursement, providing government subsidies, and instituting income‑adjusted sliding‑scale fees—ensuring affordable treatment across all socioeconomic groups.

Foster Multi-Stakeholder Collaboration

• Cross-Sector Platforms: Establish new collaborative forums or leverage existing ones (such as the WHO/Europe Access to Novel Medicines Platform) where developers, payers, providers, and regulators can align on expectations and resolve bottlenecks.

• Patient-Centric Design: Integrate patient perspectives into trial designs, HTA evaluations, and public education efforts to maintain focus on outcomes that matter most to patients and societal health.

• Data-Sharing Initiatives: Establish shared databases and registries to pool clinical and economic data, accelerating learning and policy development across regions.

Conclusion

Psychedelic therapies present an opportunity to transform mental healthcare, providing hope for patients who have not responded to conventional treatments. With rising rates of depression, PTSD, addiction disorders, and other psychiatric conditions, there is an urgent need for innovative solutions.

The path to widespread access to these therapies is complex, particularly regarding reimbursement and market access. Current experiences with ketamine and esketamine demonstrate both the challenges and opportunities in securing coverage. Each European country presents unique evaluation and funding approaches, requiring tailored strategies. Evidence generation and analysis methods need adaptation, while infrastructure and workforce readiness uncertainties may negative influence access decisions. Without proactive solutions, Europe risks becoming less attractive for development programmes, ultimately limiting patient access to these potentially transformative treatments.

Success requires coordinated action across stakeholders. While modest adaptations to existing HTA processes—combined with stakeholder flexibility—could enable appropriate evaluation of these therapies, this demands early and sustained collaboration between developers, policymakers, payers, and providers. Key priorities include establishing clear evidence requirements, developing suitable reimbursement models, and creating practical delivery solutions. Most importantly, these discussions must begin well before regulatory approvals to ensure timely and equitable access.

The path forward demands bold action. Stakeholders must prioritise evidence generation, streamline regulatory processes, adapt HTA and reimbursement frameworks, and build the infrastructure to deliver these therapies safely and equitably. With urgency and collaboration, psychedelic therapies can move from the margins to the mainstream, delivering better patient outcomes and driving progress in mental healthcare.

Funding

Norrsken Mind, a non-profit foundation dedicated to advancing psychedelic science in Europe, supported this report through a project grant.

Norrsken Mind funds high-quality research to investigate the therapeutic potential of psychedelics for mental health disorders, along with non-profit initiatives to lay the foundation for future integration of these treatments into healthcare. The foundation has previously supported pioneering research, including the first modern Swedish clinical trial of psilocybin-assisted therapy at Karolinska Institutet.

Beyond funding scientific research, Norrsken Mind promotes education, collaboration, and stakeholder engagement to create the necessary conditions for psychedelic treatments to be rigorously studied, responsibly implemented, and accessible to patients in need.[3]3

Acknowledgements

We have many people to thank for supporting this report. We are indebted to the stakeholders who agreed to speak with us in formal and informal settings, ranging from emphatic patient advocates to forward-thinking drug developers to those with deep knowledge of the reimbursement landscape in Europe.[4]4

We are grateful to our collaborators, Viktor Chvátal and Sumudu Gouri Boyina from PsychedelicsEUROPE, Tadeusz Hawrot from PAREA, and Josh Hardman of Psychedelic Alpha, for their invaluable insights and support throughout this project. Their expertise and commitment to advancing the field have significantly enriched this report.

We sincerely thank Marcus Stråth and Emma Christersson from Norrsken Mind for their trust and unwavering support in making this report possible.

As a co-author, Martin has sought to apply an analytical mindset to the subject while drawing on his knowledge of market access from commercialisation of medicines in Europe. Co-author Floris brings a deep understanding of psychedelic research, established writing skills, and seeks to synthesise complex information into access insights for the reader.

Finally, we would like to acknowledge the countless individuals working tirelessly across Europe and globally to advance the field of psychedelic medicine. Their dedication to making these innovative treatments accessible to patients while maintaining the highest safety and efficacy standards continues to inspire our work.

How to Read This Report

This report is designed to serve multiple stakeholders, from policymakers to healthcare providers to industry professionals. While we encourage reading the complete report for a comprehensive understanding, we recognise that different readers may have specific interests. Here's a guide to help you navigate the content based on your primary interests:

For a General Overview

• the "Introduction to Psychedelics and Reimbursement" chapter provides a comprehensive introduction to psychedelics and reimbursement

• the "Critical Observations from Collaborators" chapter offers our concluding thoughts and key takeaways

For Drug Developers and Clinical Researchers

• the "The Drug Development to Reimbursement Pathway" chapter outlines the complete pathway from drug development to reimbursement at a high level

• the "Clinical Development of Psychedelic Therapies" chapter details current clinical trials and development challenges

• the "Payer and Health Technology Assessments" chapter covers health technology assessment requirements crucial for development planning

• the "Challenges and Barriers to Reimbursement" chapter highlights specific market access barriers that may be encountered

• the "Solutions and Recommendations" chapter provides actionable solutions and recommendations for evidence generation

• the "Potential Reimbursement and Access Pathways" chapter explores potential reimbursement pathways and alternative access strategies

For Policy Makers, Regulators and Payers

• the "Payer and Health Technology Assessments" chapter focuses on health technology assessment requirements and processes

• the "Reimbursement Landscape in Europe" chapter examines the reimbursement landscape across European countries

• the "Solutions and Recommendations" chapter outlines regulatory pathway modifications and policy reforms to consider

• the "Potential Reimbursement and Access Pathways" chapter explores alternative access pathways and innovative payment models

For Healthcare Providers and Clinics

• the "Reimbursement Landscape in Europe" chapter explains how reimbursement systems work in practice

• the "Solutions and Recommendations" chapter provides guidance on infrastructure development and implementation approaches

• the "Ensuring Equitable Access" chapter addresses equity considerations and practical implementation

• the "Potential Reimbursement and Access Pathways" chapter discusses various service delivery models

For Patient Advocates

• the "Challenges and Barriers to Reimbursement" chapter maps out current barriers to access

• the "Ensuring Equitable Access" chapter focuses on ensuring equitable access and ethical considerations

• the "Potential Reimbursement and Access Pathways" chapter explores alternative pathways to treatment access

Reference Materials

• Chapter 12 provides a glossary of terms and concepts

• Chapter 13 lists all sources used in the report

• Chapter 14 contains additional detailed information in the appendices

Each chapter is designed to be relatively self-contained, with key terms explained throughout. While chapters build upon each other, they can be read independently based on your interests and needs. The country-specific insights in Chapters 6 and 8 may be particularly valuable for stakeholders operating in Germany, the United Kingdom, the Netherlands, or the Czech Republic.